Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Luye Pharma Ltd at safety@luyepharma.co.uk.
Professional Resources
and helpful information
Webinar & Video
Recorded Webinar
Improving Care Quality: A Look at Treatment Pathways
ZeyzeIf® (rivastigmine) is a twice weekly transdermal patch indicated for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia.
The webinar has been developed to discuss the ever increasing challenges for Improving Care Quality for Alzheimer’s Patients in 2025 and to discuss how to optimise pathways between primary and secondary care.
Video Series
Hosted by Dr. Delia Bishara Consultant Pharmacist
This video series reviews a range of topics relating to Alzheimer’s Dementia.
Webinar
Treating Dementia in 2024: Chaired by Dr Jill Rasmussen
Our speakers discuss Optimising Pathways between Primary and Secondary Care.
Webinar
Treating Dementia in 2024: Chaired by Dr Jill Rasmussen
Our speakers discuss Optimising Pathways between Primary
and Secondary Care.
Patch and adhesive cover application¹
Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk. Adverse events should also be reported to Luye Pharma Ltd at safety@luyepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk. Adverse events should also be reported to Luye Pharma Ltd at safety@luyepharma.co.uk
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
Adverse events should also be reported to safety@luyepharma.co.uk
For prescribing information scan the QR code:
Cost savings in your area
Zeyzelf® twice weekly patches offer a compelling alternative to the
more expensive orodispersible or liquid AChE inhibitor formulations.
